Intranasal Administration of Recombinant Newcastle Disease Virus Expressing SARS-CoV-2 Spike Protein Protects hACE2 TG Mice against Lethal SARS-CoV-2 Infection

MLA

Deok-Hwan Kim, et al. “Intranasal Administration of Recombinant Newcastle Disease Virus Expressing SARS-CoV-2 Spike Protein Protects HACE2 TG Mice against Lethal SARS-CoV-2 Infection.” Vaccines, vol. 12, no. 8, Aug. 2024, p. 921. EBSCOhost, https://doi.org/10.3390/vaccines12080921.

APA

Deok-Hwan Kim, Jiho Lee, Da-Ye Lee, Seung-Hun Lee, Jei-Hyun Jeong, Ji-Yun Kim, Jiwon Kim, Yang-Kyu Choi, Joong-Bok Lee, Seung-Young Park, In-Soo Choi, Sang-Won Lee, Sungsu Youk, & Chang-Seon Song. (2024). Intranasal Administration of Recombinant Newcastle Disease Virus Expressing SARS-CoV-2 Spike Protein Protects hACE2 TG Mice against Lethal SARS-CoV-2 Infection. Vaccines, 12(8), 921. https://doi.org/10.3390/vaccines12080921

Chicago

Deok-Hwan Kim, Jiho Lee, Da-Ye Lee, Seung-Hun Lee, Jei-Hyun Jeong, Ji-Yun Kim, Jiwon Kim, et al. 2024. “Intranasal Administration of Recombinant Newcastle Disease Virus Expressing SARS-CoV-2 Spike Protein Protects HACE2 TG Mice against Lethal SARS-CoV-2 Infection.” Vaccines 12 (8): 921. doi:10.3390/vaccines12080921.